Medical-Development Biotech stocks retreated 4% Wednesday, with Rapport Therapeutics, Climb Bio, and Cullinan Therapeutics leading the decline as the broader sector group struggles.
Rapport Therapeutics was explicitly named as one of the hardest-hit biotech stocks as the Medical-Development Biotech group fell 4%.
Climb Bio was explicitly named as one of the hardest-hit biotech stocks in the sector-wide slump.
Cullinan Therapeutics was explicitly named as one of the hardest-hit biotech stocks as the group declined 4%.
The Medical-Development Biotech industry group fell 4% on Wednesday, dragging down several key players in the sector. Rapport Therapeutics, Climb Bio, and Cullinan Therapeutics emerged as the hardest-hit stocks among the 500 companies currently lacking a commercial product.
The stocks are part of the Medical-Development Biotech group, which fell 4% collectively as investors pulled back from companies that have not yet launched a commercial product.